Innoviva Q1 net income $34.9M ($0.51 EPS); GSK royalties $60.3M

Innoviva, Inc.

2023-Q1 EPS reported $0.42 revenue$76,372,000

Net income $34.9M ($0.51 basic EPS) vs $15.8M ($0.23) YoY.
GSK royalty revenue $60.3M, down from $93.5M YoY due to TRELEGY royalty sale in July 2022.
Net product sales & license revenue $19.5M ($9M GIAPREZA, $2.5M XERAVA, $8M milestone from China XERAVA approval).
Repurchased $40.3M of common stock (3.4M shares); paid off $96.2M of 2023 convertible notes.
FDA advisory committee unanimously voted 12-0 for sulbactam-durlobactam; PDUFA target date May 29, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Innoviva, Inc. reported first quarter ended March 31, 2023 results: net income Net income was $34.9 million, EPS $0.51 basic per share.

Period: first quarter ended March 31, 2023
Net income: Net income was $34.9 million
EPS: $0.51 basic per share
Result: reported results

Exact text from the filing

Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended March 31, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Innoviva, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-057825

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.